130 related articles for article (PubMed ID: 36565290)
1. Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity-induced rash in patients with multiple myeloma.
Shamriz O; Parnasa E; Rubin L; Talmon A; Ribak Y; Lebel E; Vainstein V; Aumann S; Saban R; Gatt ME; Tal Y
Eur J Haematol; 2023 Apr; 110(4):407-413. PubMed ID: 36565290
[TBL] [Abstract][Full Text] [Related]
2. Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center.
Yau P; Jimenez-Zepeda VH; Bailey K; Duggan P; Tay J; Bahlis NJ; Neri P; McCulloch S
Leuk Lymphoma; 2019 Dec; 60(13):3199-3203. PubMed ID: 31190585
[TBL] [Abstract][Full Text] [Related]
3. Simple desensitization protocol for multiple myeloma patients with lenalidomide-induced skin rash: Case series.
Sugi T; Mita M; Yasu T; Ohara S; Uchida T; Inoue M; Hagihara M
J Clin Pharm Ther; 2021 Dec; 46(6):1792-1795. PubMed ID: 33960000
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.
Lee MJ; Wickner P; Fanning L; Schlossman R; Richardson P; Laubach J; Castells M
Br J Haematol; 2014 Oct; 167(1):127-31. PubMed ID: 24824093
[No Abstract] [Full Text] [Related]
5. A practical 16-day desensitization protocol in lenalidomide-induced non-immediate hypersensitivity reactions.
Demir S; Gelincik A; Coskun R; Ozkan G; Demir N; Paksoy N; Beyaz S; Colakoglu B; Kalayoglu-Besisik S; Nalcacı M; Buyukozturk S
Ann Allergy Asthma Immunol; 2019 Oct; 123(4):394-397. PubMed ID: 31400463
[TBL] [Abstract][Full Text] [Related]
6. [Successful management of drug-induced skin rash in a relapsed multiple myeloma patient with pomalidomide desensitization].
Hagihara M; Ide S; Ohara S; Uchida T; Inoue M; Hua J
Rinsho Ketsueki; 2019; 60(2):137-139. PubMed ID: 30842382
[TBL] [Abstract][Full Text] [Related]
7. Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma.
Barley K; He W; Agarwal S; Jagannath S; Chari A
Leuk Lymphoma; 2016 Nov; 57(11):2510-5. PubMed ID: 26943456
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide Desensitization for Delayed Cutaneous Reaction: A Case Series and Review of the Literature.
Ali SB; Lee WI; Horvath N; Le TA; Smith W; Hissaria P
J Allergy Clin Immunol Pract; 2023 May; 11(5):1503-1508. PubMed ID: 36738926
[TBL] [Abstract][Full Text] [Related]
9. Analysis of risk factors for lenalidomide-associated skin rash in patients with multiple myeloma.
Sugi T; Nishigami Y; Saigo H; Hanai H; Takabatake K; Mita M; Ohara S; Ide S; Uchida T; Inoue M; Hagihara M
Leuk Lymphoma; 2021 Jun; 62(6):1405-1410. PubMed ID: 33509006
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
11. Successful desensitization procedure to lenalidomide in a patient with delayed hypersensitivity confirmed with a positive LTT.
Lazzarato I; Gonzalez-Muñoz M; Heredia R; Castellar PharmG FR; López de la Guía A; Cabañas R; Fiandor A; Dominguez-Ortega J
Eur Ann Allergy Clin Immunol; 2020 Sep; 52(5):235-237. PubMed ID: 32374557
[No Abstract] [Full Text] [Related]
12. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
[TBL] [Abstract][Full Text] [Related]
13. Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis.
Nardone B; Wu S; Garden BC; West DP; Reich LM; Lacouture ME
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):424-9. PubMed ID: 23769670
[TBL] [Abstract][Full Text] [Related]
14. Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma.
Boruah PK; Bolesta S; Shetty SM
Pharmacotherapy; 2011 Sep; 31(9):925. PubMed ID: 21923596
[TBL] [Abstract][Full Text] [Related]
15. Impact of prior bortezomib therapy on the incidence of lenalidomide-induced skin rash in multiple myeloma: a propensity score-matched multi-institutional cohort study.
Dote S; Ito K; Itakura S; Yasu T; Hira D; Noda S; Yamada S; Kobayashi Y; Terada T
Leuk Lymphoma; 2019 Dec; 60(12):2975-2981. PubMed ID: 31046497
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
[TBL] [Abstract][Full Text] [Related]
17. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
[TBL] [Abstract][Full Text] [Related]
18. Desensitization in delayed drug hypersensitivity reactions -- an EAACI position paper of the Drug Allergy Interest Group.
Scherer K; Brockow K; Aberer W; Gooi JH; Demoly P; Romano A; Schnyder B; Whitaker P; Cernadas JS; Bircher AJ;
Allergy; 2013 Jul; 68(7):844-52. PubMed ID: 23745779
[TBL] [Abstract][Full Text] [Related]
19. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
[TBL] [Abstract][Full Text] [Related]
20. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma.
Sviggum HP; Davis MD; Rajkumar SV; Dispenzieri A
Arch Dermatol; 2006 Oct; 142(10):1298-302. PubMed ID: 17043184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
